Abstract
BackgroundWhether the ABO blood group is associated with the survival of patients with laryngeal cancer remains unknown. The purpose of this study was to investigate the association between the ABO blood group and clinicopathologic characteristics of patients with laryngeal cancer and assess whether the ABO blood group was associated with prognosis.MethodsWe analyzed the records of 1260 patients with laryngeal cancer who underwent curative treatment at Sun Yat-sen University Cancer Center between January 1993 and December 2009. The Chi-square test was used to assess the relationship between the ABO blood group and clinicopathologic characteristics. The Kaplan–Meier method was used to estimate 3-, 5-, and 10-year overall survival (OS) rates. The Cox proportional hazards model was used in univariate and multivariate analyses of OS.ResultsNo significant association was found between the ABO blood group and clinicopathologic characteristics except for primary tumor site. The median OS for patients with blood groups A, B, AB, and O were 87.0, 80.0, 90.0, and 72.5 months, respectively. The 3-, 5-, and 10-year OS rates were 82.4%, 76.0%, and 67.5% for patients with blood group A; 77.4%, 69.8%, and 58.4% for patients with blood group B; 82.2%, 73.1%, and 65.6% for patients with blood group AB; and 71.7%, 66.4%, and 55.5% for patients with blood group O, respectively. Univariate and multivariate analyses showed that the ABO blood group had significant effects on prognosis in patients with laryngeal cancer.ConclusionsThe ABO blood group is associated with survival in patients with laryngeal cancer. Patients with blood group O had significantly shorter OS than patients with other ABO blood groups.
Highlights
Whether the ABO blood group is associated with the survival of patients with laryngeal cancer remains unknown
In 1992, in a study of people living in southern Poland, Konieczna et al [4] found that the blood group A2B was present significantly more frequently in 153 patients with epiglottic cancer compared with 22,422 healthy individuals; Jin et al Chin J Cancer (2016) 35:90 the difference was not significant with respect to 3- and 5-year survival rates
The patient selection criteria were as follows: (1) each patient had complete clinicopathologic data, including age, sex, stage, smoking index, alcohol consumption, histologic differentiation, the ABO blood group, and treatment status; (2) diseases were restaged according to the 2002 Union for International Cancer Control (UICC) cancer staging system, and no patient had distant metastasis at the time of initial staging; and (3) patients were initially treated with curative intent by one or a combination of surgery, radiation therapy, and chemotherapy
Summary
Whether the ABO blood group is associated with the survival of patients with laryngeal cancer remains unknown. In 1992, in a study of people living in southern Poland, Konieczna et al [4] found that the blood group A2B was present significantly more frequently in 153 patients with epiglottic cancer compared with 22,422 healthy individuals; Jin et al Chin J Cancer (2016) 35:90 the difference was not significant with respect to 3- and 5-year survival rates. In 2000, Nowinska et al [6] retrospectively studied yet another population living in southern Poland and found that differences among distinct ABO blood groups were not significant between 205 laryngeal cancer patients and 5168 healthy individuals. Few studies have examined the effect of the ABO blood group on the survival of patients with laryngeal cancer. Adam et al [3] reported no association between the ABO blood group and 5 year survival and mortality in 143 laryngeal cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
